The Amgen Golden Ticket Award, now in its third year, showcases Amgen's and NSG BioLabs' efforts to support high-growth startups in a nurturing ecosystem, with a doubling of applicants compared to last year

安进金奖现已进入第三年，展示了安进和NSG生物实验室在培育生态系统中支持高增长初创企业的努力，申请人数比去年翻了一番

Amgen and NSG BioLabs extended the Golden Ticket partnership for another three years demonstrating continued commitment to advancing Singapore's biotech sector

安进和NSG生物实验室将金票合作关系延长了三年，表明他们继续致力于推进新加坡的生物技术行业

This year's winner, PairX Bio, will receive valuable access to mentorship from Amgen's thought leaders and a year-long residency at NSG BioLabs, a space meticulously designed for scientists

今年的获奖者PairX Bio将获得安进思想领袖的宝贵指导，并在NSG BioLabs居住一年，这是一个为科学家精心设计的空间

NSG BioLabs has also partnered with CapitaLand to establish its fourth site, bringing its total size to 70,000 square feet, set to be Southeast Asia's largest co-working laboratory space

NSG生物实验室还与凯德置地合作建立了第四个场地，总面积达到70000平方英尺，将成为东南亚最大的合作实验室空间

SINGAPORE, July 17, 2024 /PRNewswire/ -- Leading global biotechnology company Amgen, and NSG BioLabs, Singapore's largest provider of biotech co-working biosafety level 2 laboratories, celebrate the successful conclusion of their third annual Amgen Golden Ticket competition today. This year marked a significant milestone with a doubling of applicants compared to last year, reflecting burgeoning interest in the industry and the vibrancy of Singapore's biotech ecosystem.

新加坡，2024年7月17日，全球领先的生物技术公司安进（Amgen）和新加坡最大的生物技术合作生物安全二级实验室供应商NSG BioLabs今天庆祝其第三届年度安进（Amgen）金票竞赛圆满结束。今年是一个重要的里程碑，申请人数比去年翻了一番，反映出对该行业的兴趣日益浓厚，以及新加坡生物技术生态系统的活力。

Collaborative initiatives, such as the Amgen Golden Ticket, exemplify the commitment of industry leaders like Amgen and NSG BioLabs to advancing Singapore's biotech landscape and supporting innovative and high-growth startups. Building on the success of the awards programme, Amgen and NSG BioLabs are pleased to announce the extension of the Amgen Golden Ticket Programme for another three years..

安进金券等合作举措体现了安进和NSG BioLabs等行业领导者致力于推进新加坡生物技术领域，支持创新型和高增长创业公司。在奖项计划取得成功的基础上，安进和NSG生物实验室很高兴宣布将安进金奖计划再延长三年。。

Continue Reading

继续阅读

PairX Bio named winner of the Amgen x NSG BioLabs Golden Ticket Awards 2024. (PRNewsfoto/NSG BioLabs)

PairX Bio荣获2024年安进x NSG生物实验室金奖。（PRNewsfoto/NSG生物实验室）

Amgen (PRNewsfoto/NSG BioLabs)

安进（PRNewsfoto/NSG生物实验室）

This year, PairX Bio, a pre-clinical stage biotech company that pairs novel biology-based cancer targets with optimal therapeutic modalities to revolutionise cancer-selective biologics, was awarded the Amgen Golden Ticket. This entitles them to invaluable mentorship opportunities within Amgen's expansive network of scientific and business leaders.

今年，PairX Bio，一家临床前阶段的生物技术公司，将基于生物学的新型癌症靶标与最佳治疗方式相结合，以彻底改变癌症选择性生物制剂，获得了安进金奖。这使他们有权在安进庞大的科学和商业领袖网络中获得宝贵的指导机会。

PairX Bio will also benefit from a year-long residency at NSG BioLabs' fully-equipped lab space designed with scientists in mind..

PairX Bio还将在NSG BioLabs设备齐全的实验室空间居住一年，该实验室以科学家为中心设计。。

'We are thrilled to witness the growing impact of the Amgen Golden Ticket Programme over the past three years in Singapore. Like other successful Golden Ticket initiatives sponsored by Amgen around the world, this programme has been pivotal in fostering innovation and supporting promising companies such as PairX Bio.

“我们很高兴看到安进金票计划在过去三年中在新加坡产生了越来越大的影响。与安进在世界各地赞助的其他成功的金票计划一样，该计划在促进创新和支持PairX Bio等有前途的公司方面发挥了关键作用。

Their breakthrough research in oncology holds the potential to drive impactful advancements in patient care in the future. We take pride in contributing to the biotech sector in Singapore and remain committed to nurturing the next generation of biotech leaders with our extended commitment through 2027,' said Dr.

。我们为为新加坡的生物技术行业做出贡献而感到骄傲，并将继续致力于培养下一代生物技术领导者，并承诺到2027年。

Alan Russell, Vice President, Biologics Therapeutic Discovery, Amgen. .

。。

'We are deeply honoured to receive Amgen's prestigious Golden Ticket Award. This recognition validates the groundbreaking work of our team to develop next-generation cancer-selective biologics. We are grateful for Amgen's support and proud to be part of the vibrant life sciences ecosystem in Singapore, where collaboration and innovation are driving significant advancements in healthcare.

“我们非常荣幸获得安进享有盛誉的金票奖。这一认可验证了我们团队开发下一代癌症选择性生物制剂的开创性工作。我们感谢安进的支持，并为成为新加坡充满活力的生命科学生态系统的一部分而感到骄傲，在新加坡，合作和创新正在推动医疗保健的重大进步。

We look forward to leveraging this opportunity to further our mission of transforming cancer treatment and improving patient outcomes,' said David M. Epstein, Co-founder, CEO and President, PairX Bio.The accolade follows in the footsteps of past recipients like Albatroz Therapeutics, a pre-clinical stage biotech company that develops therapeutic antibodies to treat solid tumors, and VerImmune, an immuno-oncology company focused on redirecting pre-existing immune memory from past infections or childhood vaccines to target cancer.

PairX Bio联合创始人、首席执行官兼总裁大卫·M·爱泼斯坦（DavidM.Epstein）表示，我们期待着利用这一机会，进一步推进我们转变癌症治疗和改善患者预后的使命。这一荣誉是继Albatroz Therapeutics（一家开发治疗实体瘤的治疗性抗体的临床前阶段生物技术公司）和Verimune（一家专注于将过去感染或儿童疫苗中预先存在的免疫记忆重定向至靶向癌症的免疫肿瘤学公司）等过去接受者之后获得的。

Both winners benefited from the mentorship and access to industry that helped them accelerate their research and development efforts. Albatroz raised their seed funding round of US$3 million in early 2023i while VerImmune raised US$3.1 million in 2023ii following an initial US$2.5 million raise in 2022, and achieved milestones such as a successful FDA pre-IND meetingiii.'NSG BioLabs empowers biotech startups by providing top-tier BSL-2 laboratory spaces, offering scientists a conducive environment to conduct their research, and bring their ideas to fruition.

。Albatroz在2023i年初筹集了300万美元的种子资金，而VerImmune在2022年首次筹集了250万美元后，在2023ii年筹集了310万美元，并取得了诸如FDA成功召开第三次工业发展会议（pre-IND meetingiii）等里程碑NSG BioLabs通过提供顶级BSL-2实验室空间，为科学家提供有利的环境进行研究，并将他们的想法付诸实践，从而为生物技术初创公司提供了强大的力量。

By fostering connections between leading pharmaceutical companies and pioneering startups, we cultivate collaboration that drives healthcare advancements. We deeply appreciate our strong partnership with the Amgen team and look forward to future collaborations with other industry leaders. Together, we are de.

通过培养领先制药公司和创业公司之间的联系，我们培养了推动医疗保健进步的合作。我们非常感谢我们与安进团队的强大合作关系，并期待着未来与其他行业领导者的合作。我们在一起。

i https://www.albatroztherapeutics.com/news/albatroz-therapeutics-secure-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation/

我https://www.albatroztherapeutics.com/news/albatroz-therapeutics-secure-3-million-to-develop-first-ever-therapy-blocking-a-universal-process-involved-in-the-growth-and-spread-of-cancerous-solid-tumors-and-arthritic-cartilage-degradation/

ii https://www.verimmune.com/news/verimmune-inc-announces-over-3m-additional-funding

二https://www.verimmune.com/news/verimmune-inc-announces-over-3m-additional-funding

iii https://www.verimmune.com/news/verimmune-announces-positive-pre-ind-meeting-with-fda

三https://www.verimmune.com/news/verimmune-announces-positive-pre-ind-meeting-with-fda

SOURCE NSG BioLabs

来源：NSG生物实验室